A pivotal trial in the 2nd line setting for IMPT-314 in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs CD19-CD20 bi-specific chimeric antigen receptor-T cell therapy-ImmPACT (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- 16 Jan 2025 New trial record
- 09 Jan 2025 According to an Lyell Immunopharma media release, the company planned to initiate a pivotal trial in the 2nd line setting by early 2026